Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasofoxifene + abemaciclib vs fulvestrant + abemaciclib in ER+/HER2− metastatic breast cancer with ESR1 mutation
2023-503708-10-00Phase 3Authorised
- Sponsor
- LeonaBio
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of lasofoxifene in breast cancer (2 arms), sponsored by LeonaBio. Primary endpoint: Progression-free survival. Planned start Feb 2024; status: authorised.
02
Drugs
lasofoxifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-503708-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503708-10-00.